Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Nervous System Diseases

Digestive System Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Breast Neoplasms

Melanoma

Head and Neck Neoplasms

Brain Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Urogenital Neoplasms

Gastrointestinal Diseases

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Male Urogenital Diseases

Hypoglycemic Agents

All Drugs and Chemicals

Antineoplastic Agents

Antirheumatic Agents

Dermatologic Agents

Reproductive Control Agents

Micronutrients

Hematinics

Vitamins

Insulin

Insulin, Globin Zinc

Methotrexate

Mitogens

Antimetabolites

Enzyme Inhibitors

Folic Acid

Vitamin B Complex

Folic Acid Antagonists

Immunosuppressive Agents

Immunologic Factors

Folinic Acid

Folate

Vitamin B9

IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle.

IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle. Up to 7 dose levels will be tested, starting with 0.05 microequivalents per kg and up to 2.5 microequivalents per kg.

IGF-Methotrexate conjugate

Neeta Venepalli, MD

This phase I dose escalation study will evaluate IGF-Methotrexate conjugate (765IGF-MTX) in patients with advanced, previously treated tumors. 765IGF-MTX is administered as an IV infusion over 1 hour on days 1, 8 and 15 of a 28 day cycle. Treatment continues until disease progression, unacceptable toxicity, or patient refusal. Assessment of response will be confirmed with imaging studies performed at the end of cycle 2 +/- 7 days, and every 2 weeks thereafter.

Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R

STM-02: Phase I Study of IGF-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing Insulin-like Growth Factor Receptor 1 (IGF-1R)

The primary objective is to determine the maximum tolerated dose (MTD) of 765IGF-MTX by evaluation of toxicity for the treatment of advanced, previously treated malignancies that express IGF-1R.

Characterize adverse effects (AE) of 765IGF-MTX in patients with advanced, previously treated malignancies as defined by CTCAE v 4.0.

Evaluate clinical response of 765IGF-MTX in patients with advanced, previously treated malignancies. Disease response will be assessed every 8 weeks while on study treatment using the Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1).

IGF Oncology, LLC

Rare Diseases

Neuroendocrine Tumors

Sarcoma, Ewing

Neuroectodermal Tumors, Primitive, Peripheral

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Neuroendocrine Tumor

Pancreatic Neuroendocrine Tumor

Neuroepithelioma

Using a dose-escalation design, PAC-1 is administered orally on days 1-21, at the assigned dose, of a 28-day cycle.

PAC-1 is taken orally on days 1-21 of a 28-day cycle.

PAC-1

Oana C Danciu, M.D.

This Phase I dose escalation study will evaluate Procaspase Activating Compound-1 (PAC-1), a small molecule that activates procaspase -3 to caspase-3, resulting in apoptosis of cancer cells, in patients with advanced malignancies. As of March 1, 2019, only patients with neuroendocrine tumors will be enrolled in Component 1 of this study. PAC-1 is taken orally on days 1-21 of a 28-day cycle. The maximum tolerated dose (MTD) of PAC-1 (5 dose levels) will be determined using a modified-Fibonacci dose-escalation 3+3 design. Treatment continues until disease progression, unacceptable toxicity, physician discretion, or patient refusal.

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

The primary objective of this study component is to determine the maximum tolerated dose (MTD) of PAC-1 in patients with advanced, previously treated malignancy, by evaluation of toxicity and tolerability.

Characterize adverse effects (AE) of PAC-1 in patients with advanced malignancy.

Evaluate clinical response of PAC-1 in patients with solid tumors (RECIST v 1.1).

Evaluate clinical response of PAC-1 in patients with lymphoma (Deauville PET Criteria).

University of Illinois at Chicago

Vanquish Oncology, Inc.

Assistant Professor

Symptoms and General Pathology

Blood and Lymph Conditions

Immune System Diseases

Syndrome

Leukemia

Leukemia, Lymphoid

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Leukemia, Lymphocytic, Chronic, B-Cell

Preleukemia

Myelodysplastic Syndromes

Hematologic Diseases

Bone Marrow Diseases

Precancerous Conditions

Myeloid Leukemia

Acute Myeloid Leukemia

Chronic Graft Versus Host Disease

Acute Non Lymphoblastic Leukemia

Chronic Lymphocytic Leukemia

Acute Graft Versus Host Disease

Venetoclax

Acalabrutinib

Zanubrutinib

Ibrutinib

Gilteritinib

Midostaurin

Quizartinib

Crenolanib

Dose Escalation and Expansion; CG-806 will be given orally in ascending doses in patients with relapsed or refractory AML or higher-risk MDS (escalation cohort), until the maximum tolerated dose or candidate recommended Phase 2 dose is reached. Followed up by up to 50 patients enrolled in the expansion cohort at the recommended dose.

CG-806 will be given orally in ascending doses starting at 450 mg PO BID until the maximum tolerated dose or candidate recommended Phase 2 dose is reached.

CG-806

Rafael Bejar, MD, PhD

This study is being done to evaluate the safety, tolerability and antitumor activity of oral CG-806 (luxeptinib) for the treatment of patients with Acute Myeloid Leukemia (except APML), secondary AML, therapy-related AML, or higher-risk MDS, whose disease has relapsed, is refractory or who are ineligible for or intolerant of intensive chemotherapy or transplantation.

This is a multicenter, open-label, Phase 1 a/b dose escalation study of safety, pharmacodynamics, and pharmacokinetics of CG-806 in ascending cohorts (3+3 design) to determine the MTD or recommended dose in patients with relapsed or refractory Acute Myeloid Leukemia (except APML), secondary AML, therapy-related AML, or higher-risk MDS whose disease has relapsed, is refractory or who are ineligible for or intolerant of intensive chemotherapy or transplantation. This is to be followed by a cohort expansion phase.

A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

A Phase 1a/b Trial of CG-806 in Patients With Relapsed/Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndromes

Patients will be assessed for adverse events during all cycles of treatment and for dose limiting toxicities in Cycle 1 (28-days). Dose escalation to a higher dose level will be considered if none of the first three patients who complete Cycle 1 (28-days) at a given dose level experience a dose limiting toxicity or if only 1 of 6 patients at a given dose level experience a dose-limiting toxicity.

To determine the dose of CG-806 given orally every 12 hours daily that maintains a biologically active plasma concentration during 28-day cycles.

To establish the maximum tolerated dose and/or recommended Phase 2 dose (RP2D) of CG-806 for future clinical trials in patients with AML and other advanced myeloid malignancies.

Pharmacokinetics variables including maximum plasma concentration at various timepoints.

Pharmacokinetics variables including minimum plasma concentration at various timepoints.

Pharmacokinetics variables including plasma concentration at various timepoints.

To determine the ability of CG-806 to modulate the expression or activity of pharmacodynamic biomarkers of drug effect.

To assess patients for evidence of anti-tumor activity of CG-806 based on hematologic, bone marrow, physical examination, and FDG PET-CT imaging evaluations.

Compare G1 to G3 pharmacokinetics variables including maximum plasma concentration (Cmax)

Compare G1 to G3 Pharmacokinetics variables including minimum plasma concentration (Cmin)

Compare G1 to G3 Pharmacokinetics variables including area under the curve (AUC)

Compare G1 to G3 Pharmacokinetics variables including volume of distribution

Compare G1 to G3 Pharmacokinetics variables including clearance

Compare G1 to G3 Pharmacokinetics variables including plasma half-life.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R	NCT02045368	Breast Cancer Brain Cancer Gastrointestina... Genitourinary C... Gynecologic Can... Head and Neck C... Melanoma Thoracic Cancer...	IGF-Methotrexat...	18 Years -	IGF Oncology, LLC
Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R	NCT02045368	Breast Cancer Brain Cancer Gastrointestina... Genitourinary C... Gynecologic Can... Head and Neck C... Melanoma Thoracic Cancer...	IGF-Methotrexat...	18 Years -	IGF Oncology, LLC
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1	NCT02355535	Solid Tumor Pancreatic Neur... Neuroendocrine ...	PAC-1	18 Years - 85 Years	Vanquish Oncology, Inc.
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1	NCT02355535	Solid Tumor Pancreatic Neur... Neuroendocrine ...	PAC-1	18 Years - 85 Years	Vanquish Oncology, Inc.
A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS	NCT04477291	Acute Myeloid L... Myelodysplastic...	CG-806	18 Years -	Aptose Biosciences Inc.
Study of Insulin-like Growth Factor (IGF)-Methotrexate Conjugate in the Treatment of Advanced Tumors Expressing IGF-1R	NCT02045368	Breast Cancer Brain Cancer Gastrointestina... Genitourinary C... Gynecologic Can... Head and Neck C... Melanoma Thoracic Cancer...	IGF-Methotrexat...	18 Years -	IGF Oncology, LLC

Spots Global Cancer Trial Database for intolerant

Every month we try and update this database with for intolerant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for intolerant

Every month we try and update this database with for intolerant cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for intolerant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.